Apr 18, 2017 - The healthcare industry is much more than Obamacare and drug prices as many companies are using new technologies to create breakthroughs in medicine.
Apr 18, 2017 - Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals
Apr 18, 2017 - Drugmakers get denied, Chipotle continues gains, and earnings season gets under way. Investors have remained optimistic ahead of what could be a tumultuous week.
Apr 17, 2017 - Despite a climbing market, these stocks fell. Find out why.
Apr 17, 2017 - Shares of Incyte and Eli Lilly are reeling following the FDA's rejection of their once-daily rheumatoid arthritis pill.
Apr 17, 2017 - The FDA has rejected Eli Lilly and Incyte's application for approval of a potential blockbuster rheumatoid arthritis drug.
Apr 17, 2017 - Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.
Apr 17, 2017 - Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.
Apr 14, 2017 - Eli Lilly and Incyte said the U.S. Food and Drug Administration didn’t approve their new drug application for a rheumatoid arthritis treatment that some analysts estimate could generate more than $2 billion in annual sales.
Apr 14, 2017 - A Lilly-Incyte rheumatoid arthritis drug won’t come to market any time soon after the FDA’s surprise rejection of the treatment.